Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy

Author: Hibino, Emi; Hiroaki, Hidekazu

Description: The tumor suppressor protein p53, a transcription product of the anti-oncogene TP53, is a critical factor in preventing cellular cancerization and killing cancer cells by inducing apoptosis. As a result, p53 is often referred to as the “guardian of the genome.” Almost half of cancers possess genetic mutations in the TP53 gene, and most of these mutations result in the malfunction of p53, which promotes aggregation. In some cases, the product of the TP53 mutant allele shows higher aggregation propensity; the mutant co-aggregates with the normal (functional) p53 protein, thus losing cellular activity of the p53 guardian. Cancer might also progress because of the proteolytic degradation of p53 by activated E3 ubiquitination enzymes, MDM2 and MDM4. The inhibition of the specific interaction between MDM2 (MDM4) and p53 also results in increased p53 activity in cancer cells. Although the molecular targets of the drugs are different, two drug discovery strategies with a common goal, “rescuing p53 protein,” have recently emerged. To conduct this approach, various biophysical methods of protein characterization were employed. In this review, we focus on these two independent strategies based on the unique biophysical features of the p53 protein.

Subject headings: Amyloid; Drugs targeting p53; Mutant p53 proteins; Oncoprotein MDM2; Tumor suppressor p53; p53 pathway functions

Publication year: 2022

Journal or book title: Biophysical Reviews

Volume: 14

Issue: 1

Pages: 267-275

Find the full text: https://link.springer.com/article/10.1007/s12551-021-00915-5

Find more like this one (cited by): https://scholar.google.com/scholar?cites=15826704026570516747&as_sdt=1000005&sciodt=0,16&hl=en

Serial number: 3862